Bayer’s Turnaround Test: Supreme Court Weighs Roundup Fate as Q1 Results Loom

Bayer stock slips below key moving average as Supreme Court weighs Roundup litigation; analysts see 24% upside on legal resolution.

The week ahead carries more than the usual weight for Bayer. Between a US Supreme Court hearing that could reshape its legal landscape and the release of first-quarter earnings, the German conglomerate faces a defining moment in its long-running restructuring saga. Investors, already on edge after the stock slipped below a key technical threshold, are watching both events with unusual intensity.

A Legal Pivot Point in Washington

Monday’s oral arguments before the Supreme Court center on a question with billions of dollars in implications: can federal law limit the scope of thousands of state-level lawsuits over the weedkiller Roundup? Since Bayer’s $63 billion acquisition of Monsanto in 2018, the company has been mired in litigation with plaintiffs alleging glyphosate causes cancer. A favorable ruling from the justices could clear the way for a comprehensive settlement, a scenario that outgoing finance chief Wolfgang Nickl recently described with cautious optimism.

The stakes are enormous. Bayer has set aside substantial provisions for legal costs, but a decisive Supreme Court signal would remove one of the heaviest weights on the balance sheet. Chief executive Bill Anderson has pledged to significantly reduce legal exposure by the end of 2026. Market reaction to any positive development would likely be swift—analysts estimate the current share price already discounts much of the legal risk.

Technical Damage and Analyst Conviction

The stock closed Friday at €38.50, down 3.85% on the day and roughly 4% for the week. That decline pushed the shares below the 100-day moving average of €40.59, a classic sell signal in charting terms. The 50-day line was also breached earlier in the week. From the 52-week high of €49.17, the stock now trades about 22% lower. The relative strength index stands at 46.8, neutral territory that suggests no oversold bounce is imminent.

Yet the technical picture has done little to shake analyst confidence. Barclays rates Bayer “overweight” with a €48 target. Goldman Sachs and UBS both recommend buying, while JP Morgan maintains its “overweight” call. The lone holdout is Deutsche Bank with a “hold” rating. The consensus price target of €47.63 implies roughly 24% upside from current levels. The message from the sell side is clear: the legal overhang is priced in, and any resolution would unlock significant value.

Shareholder Sentiment at the AGM

Friday’s annual general meeting gave large investors a platform to voice their frustrations and expectations. Representatives from Deka, DWS, and Union Investment acknowledged operational progress but demanded clearer strategic direction. Deka’s Ingo Speich called the current year decisive for Bayer’s future, urging management to conduct an open-ended review of the corporate structure once legacy legal issues are resolved.

Union Investment, however, backed Anderson’s existing strategy, arguing against an immediate spin-off of the consumer health division. Despite the tension, shareholders voted to discharge the board for the past fiscal year.

Operational Progress Amid Cost Cutting

Bayer delivered on its 2024 targets. Revenue reached €45.6 billion, while adjusted earnings per share came in at €4.91. Net debt was trimmed to just under €30 billion. The restructuring, however, has come at a human cost: roughly 14,000 positions have been eliminated since the overhaul began, including 4,700 last year alone.

The cost-cutting drive will soon have a new steward. Dr. Judith Hartmann takes over as chief financial officer in early June, replacing Wolfgang Nickl. Her arrival coincides with a period when financial discipline remains paramount.

What’s Next on the Calendar

Monday also marks the ex-dividend date for Bayer shares, with the payout scheduled for Wednesday. Then, on May 12, management will release first-quarter results. For the full year, Bayer targets adjusted operating earnings between €9.6 billion and €10.1 billion.

The immediate focus, however, remains on Washington. If the Supreme Court signals a narrowing of litigation avenues, the €40 mark could come back into play quickly. An unclear or unfavorable outcome would likely keep the stock under pressure, with macro events like the Federal Reserve’s April 29 decision serving as background noise. For Bayer, this week is anything but routine.